NRAS and neoplasm: Approximately 30% of CMM patients present tumors with NRAS mutations4,5 and are therefore not eligible for inhibitors of mutated BRAF, as these drugs appear to be tumor promoting for these patients6, necessitating alternate therapy approaches for targeted therapy.